Current Brain, Head & Neck Cancer Clinical Trials

ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study) (ACTION)

Recurrent GBM Treated With Neurosurgical Resection and IORT Using the Xoft Axxent eBx System and Bevacizumab (IORT)

(TRIDENT) Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With Radiation Therapy Temozolomide for the Treatment of Newly Diagnosed GBM (EF-32)

A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme (WHO Grade IV)

Intermediate-size Expanded Access to ONC201 for Patients with H3 K27M-mutant and/or Midline Gliomas

Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma

A First in Human Study To Evaluate the Safety and Tolerability of AdAPT-001 in Subjects With Refractory Solid Tumors (BETA-PRIME)

Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209)